Choosing the right dose is one of the most important decisions in early clinical development, and for most modern therapies the maximum tolerated dose is no longer the answer. In this on-demand webinar hosted by SelectScience, Evotec clinical operations and biometry experts show how model-informed drug development (MIDD) brings safety, PK/PD, biomarker and efficacy data together, so dose decisions are made on the right evidence at the right time.
Watch to Learn:
- Why early development is moving from dose escalation to dose optimization, and what FDA Project Optimus and ICH M15 mean in practice
- How safety, PK/PD, biomarker and early efficacy data can be combined to support dose and cohort decisions while the study is running
- What to plan upfront, from data flow to governance, so the right evidence is ready when each decision comes up
Speakers:
Watch the Webinar
If the webinar has not loaded above, please click the link here.